CL3-16257-056 |
Effects of ivabradine on cardiovascular events in patients with stable coronary artery disease and left…
|
IVABRADINE, S016257
|
Phase 3
|
Cardiovascular Diseases
|
|
CL3-12911-040 |
Knee joint replacement over 5 years in patients with knee osteoarthritis. A long term follow…
|
STRONTIUM RANELATE, S012911
|
Phase 3
|
Rheumatology
|
|
CL3-12911-038 |
A 24 months, prospective, randomized, double-blind study to assess the effect of daily oral administration…
|
STRONTIUM RANELATE, S012911
|
Phase 3
|
Rheumatology
|
|
CL3-12911-037 |
A prospective, controlled, double blind, international study to assess the effects of strontium ranelate vs.…
|
STRONTIUM RANELATE, S012911
|
Phase 3
|
Rheumatology
|
|
CL3-12911-036 |
Effect of strontium ranelate (2g per day) in the management of long bone fractures with…
|
STRONTIUM RANELATE, S012911
|
Phase 3
|
Rheumatology
|
|
CL3-12911-035 |
A multicenter, prospective, randomized, double-blind, placebo-controlled, international study to assess the effects of 2g per…
|
STRONTIUM RANELATE, S012911
|
Phase 3
|
Rheumatology
|
|
CL3-12911-032 |
The efficacy and safety of 2g strontium ranelate in the treatment of male osteoporosis. A…
|
STRONTIUM RANELATE, S012911
|
Phase 3
|
Rheumatology
|
|
CL3-12911-030 |
A double-blind, multicentric, multinational randomised study to assess the effects of two years administration of…
|
STRONTIUM RANELATE, S012911
|
Phase 3
|
Rheumatology
|
|
CL3-12911-028 |
Long-term effects of strontium ranelate on knee osteoarthritis symptoms. A 2-year prospective, randomised, placebo-controlled study.
|
STRONTIUM RANELATE, S012911
|
Phase 3
|
Rheumatology
|
|
CL3-12911-025 |
A double-blind, multicenter, international randomised study to assess the effects of 6 months or 12…
|
STRONTIUM RANELATE, S012911
|
Phase 3
|
Rheumatology
|
|
CL3-12911-022 |
The efficacy and safety of two doses of strontium ranelate versus placebo administered orally for…
|
STRONTIUM RANELATE, S012911
|
Phase 3
|
Rheumatology
|
|
CL3-12911-019 |
A double-blind, multicentric, multinational randomised study to assess the effects of one year administration of…
|
STRONTIUM RANELATE, S012911
|
Phase 3
|
Rheumatology
|
|
CL3-12911-018 |
The efficacy and safety of two doses of strontium ranelate (1g and 2g per day)…
|
STRONTIUM RANELATE, S012911
|
Phase 3
|
Rheumatology
|
|
CL3-12911-016 |
The efficacy and safety of 2g strontium ranelate in the treatment of osteoporosis in men.…
|
STRONTIUM RANELATE, S012911
|
Phase 3
|
Rheumatology
|
|
CL3-12911-012 |
SOTI and TROPOS phase III studies open-label extension. The long term efficacy and long term…
|
STRONTIUM RANELATE, S012911
|
Phase 3
|
Rheumatology
|
|
CL3-09490-144 |
Effects of perindopril on mortality/morbidity in patients with stable coronary artery disease without clinical heart…
|
PERINDOPRIL TERT BUTYLAMINE, S009490
|
Phase 3
|
Cardiovascular Diseases
|
|
CL3-06911-003 |
The efficacy and safety of a daily oral administration of S06911 (strontium ranelate 2g/vitamin D3…
|
STRONTIUM RANELATE, VITAMINE D, S006911
|
Phase 3
|
Rheumatology
|
|
CL3-06911-002 |
The efficacy and safety of a daily oral administration of S06911 (strontium ranelate 2g/vitamin D3…
|
STRONTIUM RANELATE, VITAMINE D, S006911
|
Phase 3
|
Rheumatology
|
|
CL3-06795-008 |
Clinical acceptability of trimetazidine 80 mg once daily compared to trimetazidine 35 mg twice daily…
|
TRIMETAZIDINE, S006795
|
Phase 3
|
Cardiovascular Diseases
|
|
CL3-06790-010 |
The efficacy and safety of trimetazidine in patients with angina pectoris having been treated by…
|
TRIMETAZIDINE, S006790
|
Phase 3
|
Cardiovascular Diseases
|
|
CL3-06593-006 |
Efficacy and safety of fixed-dose combination Perindopril 5 mg / Indapamide 1.25 mg / Amlodipine…
|
AMLODIPINE, INDAPAMIDE, PERINDOPRIL ARGININE, S006593
|
Phase 3
|
Cardiovascular Diseases
|
|
CL3-06593-005 |
Evaluation of the clinical efficacy and safety of Perindopril / Indapamide / Amlodipine fixed-dose combination…
|
AMLODIPINE, INDAPAMIDE, PERINDOPRIL ARGININE, S006593
|
Phase 3
|
Cardiovascular Diseases
|
|
CL3-06490-003 |
Efficacy on systolic and diastolic blood pressure decrease and safety of once-a-day oral 5 mg…
|
PERINDOPRIL ARGININE, S006490
|
Phase 3
|
Cardiovascular Diseases
|
|
CL3-05985-018 |
Perindopril arginine/Amlodipine versus Valsartan/Amlodipine antihypertensive strategies: Efficacy and safety in mild to moderate hypertensive patients.A…
|
AMLODIPINE, PERINDOPRIL ARGININE, S005985
|
Phase 3
|
Cardiovascular Diseases
|
|
CL3-05985-017 |
Efficacy and safety of the fixed oral perindopril arginine 5 mg/ amlopidine 5 mg combination…
|
AMLODIPINE, PERINDOPRIL ARGININE, S005985
|
Phase 3
|
Cardiovascular Diseases
|
|